# Biomarker-driven Intermittent Docetaxel in Metastatic Castration-resistant Prostate Cancer

> **NCT04918810** · PHASE2 · TERMINATED · sponsor: **Australian and New Zealand Urogenital and Prostate Cancer Trials Group** · enrollment: 6 (actual)

## Conditions studied

- Castration Resistant Prostatic Cancer

## Interventions

- **DRUG:** Docetaxel intermittent

## Key facts

- **NCT ID:** NCT04918810
- **Lead sponsor:** Australian and New Zealand Urogenital and Prostate Cancer Trials Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-07-29
- **Primary completion:** 2024-11-01
- **Final completion:** 2024-11-01
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Recruitment lower than expected. The proportion of patients with mGSTPi undetectable prior to chemo. was significantly higher than anticipated. Decision made to close due to insufficient patient numbers to able to obtain meaningful data collection.
- **Last updated:** 2024-11-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04918810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04918810, "Biomarker-driven Intermittent Docetaxel in Metastatic Castration-resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04918810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*